Recruiting

Testing a New Immune-Boosting Injection for Children Undergoing Cancer Treatment

Plain-English translation of NCT04570423 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Read our Solid Tumors research guide →

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a medication called in children ages 1 month to 16 years who have solid tumors or lymphoma and are receiving . is designed to help boost the immune system and reduce the risk of serious infections that can happen when weakens the body's infection-fighting cells. The study will give the medication by injection after each round of , up to four times, and track how safe it is and how the body responds to it.

used to treat childhood cancer can dangerously lower the number of infection-fighting white blood cells in the body, putting children at high risk for serious fevers and infections. This trial exists to see if this new treatment can safely help children's immune systems recover faster between cycles and reduce these dangerous complications.

Do you qualify?

You likely qualify if…

you are between 1 month and 16 years old
you have been newly diagnosed with, or have a returning case of, a solid tumor or lymphoma without bone marrow involvement
you are about to receive chemotherapy that typically causes severe drops in white blood cells in at least 20% of patients
you have healthy kidney and liver function, as shown by recent blood tests
you have a heart ejection fraction greater than 50% (checked by heart imaging if you're receiving heart-damaging chemotherapy)
you are well enough physically to tolerate cancer treatment, as determined by your doctor

You likely don't qualify if…

you have received other immune-boosting growth factor medications (like filgrastim or pegfilgrastim) within the past 1–2 weeks
you have an active, uncontrolled infection or serious illness that would prevent you from safely receiving treatment
you have had a bone marrow transplant or stem cell transplant in the past, or your cancer involves bone marrow
you have had spine radiation therapy within 30 days before the study starts
you have a known allergy or bad reaction to similar immune-boosting growth factor medications

What participation looks like

You will continue receiving your standard as planned. After each cycle ends (cycles can last up to 28 days or longer), you will receive an injection of the new medication under the skin. This will happen up to four times as you go through your treatment. Your doctor will monitor you closely with regular blood tests and visits to watch for side effects and to see how well the medication is working to protect your immune system.

AI-generated summary from trial data · Jul 4, 2026 · Not medical advice

Trial locations(5 sites)

United States

New York Medical College, Valhalla, New York

Carolinas Medical Center/ Levine Children's Hospital, Charlotte, North Carolina

Levine Children's Health, Charlotte, North Carolina

University Hospitals Cleveland Medical Center, Cleveland, Ohio

UT MD Anderson Cancer Center, Houston, Texas